GEHC
GE HealthCare Technologies Inc.Price & Indicators
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases, calls, and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Backlog | $21.8B | first quarter 2026 | — |
| Book-to-bill | 1.07 | first quarter 2026 | — |
|
|
|||
| Total orders (organic growth) non-GAAP | 1.1% | first quarter 2026 | — |
| adjusted EBIT margin non-GAAP | 13.5% | Q1 2026 call | — |
| adjusted EPS non-GAAP | $0.99 | Q1 2026 call | — |
| Advanced Visualization Solutions EBIT margin change non-GAAP | 120 | Q1 2026 call | — |
| Advanced Visualization Solutions organic revenue growth non-GAAP | 4.4% | Q1 2026 call | — |
| free cash flow | $112M | Q1 2026 call | — |
| Imaging organic revenue growth non-GAAP | 3.8% | Q1 2026 call | — |
| orders growth | 1.1% | Q1 2026 call | — |
| organic revenue growth non-GAAP | 2.9% | Q1 2026 call | — |
| Patient Care Solutions EBIT margin change non-GAAP | -500 | Q1 2026 call | — |
| Patient Care Solutions organic revenue growth non-GAAP | -8.1% | Q1 2026 call | — |
| Pharmaceutical Diagnostics organic revenue growth non-GAAP | 9.7% | Q1 2026 call | — |
| Product revenue growth | 7.3% | Q1 2026 call | — |
| Service revenue growth | 7.5% | Q1 2026 call | — |
| Organic orders growth non-GAAP | 5.2% | Full year 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call, "filing" figures stated in the 10-K/10-Q · YoY needs the prior-year figure on file
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GEHC
this stock
GE HealthCare Technologies Inc.
|
$29.43B | -21.1% | +4.8% | 15.5 | 3.2% |
|
ABT
Abbott Laboratories
|
$163.61B | -24.7% | +5.7% | 26.3 | 1.3% |
|
SYK
Stryker Corp
|
$126.42B | -5.9% | +11.2% | 38.2 | 1.8% |
|
MDT
Medtronic plc
|
$107.36B | -12.0% | +8.4% | 22.5 | 1.5% |
|
BSX
Boston Scientific Corp
|
$66.54B | -53.0% | +5.5% | 18.7 | 1.9% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GEHC | -1.3% | +1.5% | -21.6% | +1.1% | -21.1% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | -2.7% | -2.6% | -30.7% | 0.0% | -31.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.